medcelerator · clinician one-pager
New Infusion When Soft Tissue Turns to Bone (Adult FOP)
Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP)
FDA Approved · United States · September 7, 2026
Condition: Fibrodysplasia Ossificans Progressiva
Who this is for
Pasatru (garetosmab) is an infusion every 4 weeks for adults with fibrodysplasia ossificans progressiva. The United States approved it on 19 August 2026 to reduce new bone growth and flare-ups.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761508Orig1s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/pasatru-garetosmab